OBJECTIVE: Recently, genome-wide association studies have identified 3 new susceptibility loci for Alzheimer's disease (AD), CLU, CR1, and PICALM. We leveraged available neuropsychological and autopsy data from 2 cohort studies to investigate whether these loci are associated with cognitive decline and AD neuropathology. METHODS: The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are longitudinal studies that enroll nondemented subjects and include annual clinical evaluations and brain donation at death. We evaluated CR1 (rs6656401), CLU (rs11136000), and PICALM (rs7110631) in 1,666 subjects. We evaluated associations between genotypes and rate of change in cognitive function as well as AD-related pathology. Lastly, we used pathway analysis to determine whether relationships between single nucleotide polymorphisms and cognitive decline are mediated through AD pathology. RESULTS: Among our study cohort, the mean years of follow-up were 7.8 for ROS and 4.3 for MAP. Only the CR1 locus was associated with both global cognitive decline (p = 0.011) and global AD pathology (p = 0.025). More specifically, the locus affects the deposition of neuritic amyloid plaque (p = 0.009). In a mediation analysis, controlling for amyloid pathology strongly attenuated the effect of the CR1 locus on cognitive decline. INTERPRETATION: We found that common variation at the CR1 locus has a broad impact on cognition and that this effect is largely mediated by an individual's amyloid plaque burden. We therefore highlight 1 functional consequence of the CR1 susceptibility allele and generalize the role of this locus to cognitive aging in the general population.
OBJECTIVE: Recently, genome-wide association studies have identified 3 new susceptibility loci for Alzheimer's disease (AD), CLU, CR1, and PICALM. We leveraged available neuropsychological and autopsy data from 2 cohort studies to investigate whether these loci are associated with cognitive decline and AD neuropathology. METHODS: The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are longitudinal studies that enroll nondemented subjects and include annual clinical evaluations and brain donation at death. We evaluated CR1 (rs6656401), CLU (rs11136000), and PICALM (rs7110631) in 1,666 subjects. We evaluated associations between genotypes and rate of change in cognitive function as well as AD-related pathology. Lastly, we used pathway analysis to determine whether relationships between single nucleotide polymorphisms and cognitive decline are mediated through AD pathology. RESULTS: Among our study cohort, the mean years of follow-up were 7.8 for ROS and 4.3 for MAP. Only the CR1 locus was associated with both global cognitive decline (p = 0.011) and global AD pathology (p = 0.025). More specifically, the locus affects the deposition of neuritic amyloid plaque (p = 0.009). In a mediation analysis, controlling for amyloid pathology strongly attenuated the effect of the CR1 locus on cognitive decline. INTERPRETATION: We found that common variation at the CR1 locus has a broad impact on cognition and that this effect is largely mediated by an individual's amyloid plaque burden. We therefore highlight 1 functional consequence of the CR1 susceptibility allele and generalize the role of this locus to cognitive aging in the general population.
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy Journal: Proc Natl Acad Sci U S A Date: 2005-06-02 Impact factor: 11.205
Authors: Rita J Guerreiro; John Beck; J Raphael Gibbs; Isabel Santana; Martin N Rossor; Jonathan M Schott; Michael A Nalls; Helena Ribeiro; Beatriz Santiago; Nick C Fox; Catarina Oliveira; John Collinge; Simon Mead; Andrew Singleton; John Hardy Journal: PLoS One Date: 2010-03-03 Impact factor: 3.240
Authors: David A Bennett; Julie A Schneider; Aron S Buchman; Carlos Mendes de Leon; Julia L Bienias; Robert S Wilson Journal: Neuroepidemiology Date: 2005-08-15 Impact factor: 3.282
Authors: G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman Journal: Neurology Date: 1993-02 Impact factor: 9.910
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach Journal: Neurology Date: 2002-07-23 Impact factor: 9.910
Authors: Lei Yu; Joshua M Shulman; Lori Chibnik; Sue Leurgans; Julie A Schneider; Philip L De Jager; David A Bennett Journal: Aging Cell Date: 2011-12-29 Impact factor: 9.304
Authors: Jessica R Marden; Elizabeth R Mayeda; Stefan Walter; Alexandre Vivot; Eric J Tchetgen Tchetgen; Ichiro Kawachi; M Maria Glymour Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: S Barral; T Bird; A Goate; M R Farlow; R Diaz-Arrastia; D A Bennett; N Graff-Radford; B F Boeve; R A Sweet; Y Stern; R S Wilson; T Foroud; J Ott; R Mayeux Journal: Neurology Date: 2012-04-25 Impact factor: 9.910
Authors: Andrew S P Lim; Anne-Marie Chang; Joshua M Shulman; Towfique Raj; Lori B Chibnik; Sean W Cain; Katherine Rothamel; Christophe Benoist; Amanda J Myers; Charles A Czeisler; Aron S Buchman; David A Bennett; Jeanne F Duffy; Clifford B Saper; Philip L De Jager Journal: Ann Neurol Date: 2012-09 Impact factor: 10.422
Authors: Richard Sherva; Yorghos Tripodis; David A Bennett; Lori B Chibnik; Paul K Crane; Philip L de Jager; Lindsay A Farrer; Andrew J Saykin; Joshua M Shulman; Adam Naj; Robert C Green Journal: Alzheimers Dement Date: 2013-03-25 Impact factor: 21.566